Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma, Gall Bladder Carcinoma, Solid Tumor, Non-Hodgkin's Lymphoma
Conditions
Keywords
Neoplasm
Brief summary
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
Interventions
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Part A: Histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic (solid tumors or non-Hodgkin's lymphoma). * Part B: Biliary tract carcinoma that is unresectable, recurrent, or metastatic. The participant must not have received prior systemic front-line therapy for metastatic or resectable disease. * Part A: Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Cheson Criteria. * Part B: Measurable disease as defined by RECIST v1.1. * Adequate organ function including hematologic, hepatic and renal. * Eastern Cooperative Oncology Group (ECOG) scale of 0 or 1. * Are able to swallow tablets. * For participants in Part B, a tumor tissue sample is mandatory for biomarker analysis. * Males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug. * Females with childbearing potential: Must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test ≤7 days before the first dose of study drug. * A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, breastfeeding must cease from the day of the first study drug administration until at least 3 months after the last administration.
Exclusion criteria
* Have serious pre-existing medical conditions. * Have a chronic underlying infection. * Have symptomatic central nervous system malignancy or metastasis. * Have an active fungal, bacterial, and/or known viral infection. * Part B: Have mixed hepatocellular biliary tract carcinoma histology. * Have liver cirrhosis with a Child-Pugh stage of B or higher, or have received a liver transplant. * Have a history of congestive heart failure with New York Heart Association (NYHA) class greater than 2, unstable angina, or have recent history of myocardial infarction, transient ischemic attacks, stroke, or arterial or venous vascular disease. * Have a corrected QT interval \>470 milliseconds as calculated be the Fredericia equation. * Have a second primary malignancy that, in the judgment of the investigator, and sponsor may affect the interpretation of results. * Have any evidence of clinically active interstitial lung disease (ILD).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs) | Cycle 1 (Part A = 28 Days or Part B = 21 Days) | Number of participants with DLTs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Merestinib and its Metabolites | Predose Cycle 1 Throughout the First 2 Cycles (Part A = 28-Day Cycles, Part B = 21-Day Cycles) | PK: Cmax of merestinib and its metabolites |
| PK: Area Under the Concentration Time Curve (AUC) of Merestinib and its Metabolites | Predose Cycle 1 Throughout the First 2 Cycles (Part A = 28-Day Cycles, Part B = 21-Day Cycles) | PK: AUC of merestinib and its metabolites |
| Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response | Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Estimated as up to 8 Months) | ORR: Percentage of participants with a complete or partial response |
| Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of Complete Response, Partial Response, and Stable Disease | Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Estimated as up to 8 Months) | DCR: Percentage of participants with a best overall response of complete response, partial response, and stable disease |
Countries
Japan
Outcome results
None listed